Cruz-Chan, Julio V.
Villanueva-Lizama, Liliana E.
Versteeg, Leroy
Damania, Ashish
Villar, Maria José
González-López, Cristina
Keegan, Brian
Pollet, Jeroen
Gusovsky, Fabian
Hotez, Peter J.
Bottazzi, Maria Elena
Jones, Kathryn M.
Funding for this research was provided by:
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
National Institutes of Health (P30 CA125123)
Article History
Received: 16 September 2020
Accepted: 21 December 2020
First Online: 5 February 2021
Competing interests
: All the authors of this manuscript currently are involved in a program for the development of a Chagas vaccine. FG is employed at Eisai Inc, which intends to advance E6020 as a vaccine adjuvant.